Following coadministration of the ABCB1 (P-gp) and ABCG2 (BCRP) inhibitor, elacridar (GF120918) at 100 to 1,000 mg with oral topotecan, the AUC0- ∞ of topotecan lactone and total topotecan increased approximately 2.5-fold (see section 4.5 for guidance).
Pärast ABCB1 (P- glükoproteiini) ja ABCG2 (BCRP) inhibiitori elakridari (GF120918) 100... 1000 mg manustamist koos suukaudse topotekaaniga suurenes topotekaanlaktooni ja kogu topotekaani AUC0- ∞ ligikaudu 2, 5 korda (vt lõik 4. 5).